(Q39845394)

English

Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition (English)

1 reference

Europe PubMed Central

15 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

C P Coyne

1

1 reference

Europe PubMed Central

15 September 2017

Matt K Ross

2

1 reference

Europe PubMed Central

15 September 2017

John G Bailey

3

1 reference

Europe PubMed Central

15 September 2017

publication date

1 July 2009

1 reference

Europe PubMed Central

15 September 2017

Journal of Drug Targeting

1 reference

Europe PubMed Central

15 September 2017

17

1 reference

Europe PubMed Central

15 September 2017

474-489

1 reference

Europe PubMed Central

15 September 2017

6

1 reference

Europe PubMed Central

15 September 2017

A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Targeting of human squamous carcinomas by SPA470-doxorubicin immunoconjugates.

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug.

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Her-2/neu and breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Isomer-dependent daunomycin release and in vitro antitumour effect of cis-aconityl-daunomycin

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Ongoing phase I and II studies of novel anthracyclines

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Alternative intracellular routing of ErbB receptors may determine signaling potency

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Identifiers

10.1080/10611860903012802

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39845394&oldid=2091399619"